Welcome to
Synact Pharma

Treating Inflammation through Resolution

hero-img
Intersection 6

SynAct Pharma – a clinical stage biotechnology company.

We focus our research and development on treatments with the ability to resolve rather the inhibit ongoing inflammatory processes in acute and chronic diseases.

Our lead compound, Resomelagon (AP1189), is a once-daily oral therapy that selectively activates melanocortin receptors on key effector cells in the immune system thereby increasing the body’s ability to restore immune balance.

By focusing on early intervention in chronic inflammatory diseases we aim to reduce disease progression and limit the use of less well tolerated treatment options.

A parallel track to early intervention in inflammatory diseases is the potential of our compounds to modulate hyperinflammatory stages in viral diseases, with the ability to induce faster disease control and reduce the risk of severe organ dysfunction.

This science-driven strategy opens new possibilities across a wide spectrum of inflammatory conditions, where resolution therapy with our compounds could be a new standard of care treatment.

Our Team

Meet our team of entrepreneurs and innovative scientists with vast experience from biotech.

Our Science

Our approach is centered on resolving inflammation and thereby limiting the risk for immunosuppression.

Explore the science that underpins or development strategy and clinical programs.

img-2

Disease Areas

Inflammatory conditions represent a significant unmet medical need.

Resolution of inflammation provide opp0rtunities for treating a wide range of diseases.

Development Programs

Explore our development pipeline, including our lead candidate resomelagon (API189).

img-1

Investors

Explore key information for shareholders and potential investors.

News and Media

Find our press releases, media coverage, and corporate updates. Stay connected to Synact Pharma’s journey and key developments.

Latest news and press releases

Subscribe to press releases
and reports

Loading...